1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT).
Saved in:
| Title: | 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). |
|---|---|
| Authors: | Padden-Modi, M.1 (AUTHOR), Abdel-Aty, H.1 (AUTHOR), Jones, C.2 (AUTHOR), Brown, L.C.3 (AUTHOR), Dutey-Magni, P.3 (AUTHOR), Yogeswaran, Y.3 (AUTHOR), Horsey, A.3 (AUTHOR), Amos, C.L.3 (AUTHOR), Murray, I.4 (AUTHOR), Hujairi, N.5 (AUTHOR), Tunariu, N.6 (AUTHOR), Millman, R.3 (AUTHOR), Cross, W.7 (AUTHOR), Kasivisvanathan, V.8 (AUTHOR), Parmar, M.K.3 (AUTHOR), Clarke, N.2 (AUTHOR), Gillessen, S.9 (AUTHOR), Attard, G.10 (AUTHOR), Parker, C.11 (AUTHOR), James, N.D.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS999-S1000. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.1739 |
